Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company's products include Lexapro, a selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, a N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, a beta-blocker for the treatment of hypertension, and Savella, a selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia.
|Headquarters||909 Third Avenue|
NEW YORK, NY, United States 10022
|Chairman of the Board, President, Chief Executive Officer||Howard Solomon|
|Chief Financial Officer, Executive Vice President - Finance and Administration||Francis Perier|
|Executive Vice President and Chief Commercial Officer||Elaine Hochberg|
|Senior Vice President - Sales||Jerome Lynch|
|Senior Vice President - Corporate Development and Strategic Planning||David Solomon|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||266.7M||Book Value||--|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||3.3|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-1.43%|
*GAAP = prior to non-GAAP analyst adjusted earnings.